Repare Therapeutics Inc. (RPTX) News

Repare Therapeutics Inc. (RPTX): $13.08

0.55 (+4.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RPTX News Items

RPTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RPTX News Highlights

  • RPTX's 30 day story count now stands at 2.
  • Over the past 9 days, the trend for RPTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest RPTX News From Around the Web

Below are the latest news stories about Repare Therapeutics Inc that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

Repare Therapeutics (RPTX) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 12, 2022

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass. & MONTREAL, February 03, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows:

Yahoo | February 3, 2022

Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments. Repare Therapeutics (RPTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company's shares closed last Friday at $15.23, close to its 52-week low of $13.97. According to TipRanks.

Brian Anderson on TipRanks | January 18, 2022

Repare Therapeutics highlights key milestones expected in 2022 (NASDAQ:RPTX)

Repare Therapeutics (RPTX) provides key milestones anticipated in 2022.Initiation of a monotherapy Phase 2 TRESR trial of RP-3500, for the treatment of solid tumors with…

Seeking Alpha | January 7, 2022

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

CAMBRIDGE, Mass. & MONTREAL, January 07, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.

Yahoo | January 7, 2022

Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

CAMBRIDGE, Mass. & MONTREAL, January 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.

Yahoo | January 5, 2022

Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL, January 03, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.

Yahoo | January 3, 2022

Repare Therapeutics Inc. (NASDAQ:RPTX) Expected to Post Quarterly Sales of $2.62 Million

Wall Street brokerages expect that Repare Therapeutics Inc. (NASDAQ:RPTX) will report sales of $2.62 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Repare Therapeutics earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $7.40 million. Repare Therapeutics posted []

Transcript Daily | December 22, 2021

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass. & MONTREAL, December 21, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discover and develop novel therapeutics, today announced the first patient has been dosed in the Company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule candidate targeting PKMYT1, in combination with gemcitabine for the treatment of molecularly selec

Yahoo | December 21, 2021

Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its: President and Chief Executive Officer, Lloyd Segal; Executive Vice President and Chief Financial Officer, Steve Forte; Executive Vice-President and Chief Scientific Officer, Michael Zind

Business Wire | December 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5571 seconds.